This article is more than 5 years old. Information may no longer be current.

Ocular Therapeutix requests NDA extension for Dextenza

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Ocular Therapeutix has submitted an amendment to its FDA new drug application resubmission for Dextenza, detailing a manufacturing equipment change, according to a company press release.

The company has modified a piece of equipment referenced in its NDA resubmission and will submit data on a new commercial batch to show that the change has addressed issues regarding particulate matter, the release said.

The current NDA target action date for Dextenza (dexamethasone insert 0.4 mg) is July 19. Ocular Therapeutix is asking the FDA to extend that date under PDUFA by 3 months to review the modification.

The FDA issued Form 483 to Ocular Therapeutix in May after re-inspecting manufacturing operations, focusing “on procedures and training protocols for manufacturing processes and analytical testing related to commercial manufacturing of Dextenza,” the release said.

The company submitted a close-out response to these observations on July 10.

“We believe that the recent submission of our close-out response to the Form 483 and subsequent submission of the amendment to our NDA resubmission for FDA’s consideration can support an acceptable regulatory pathway for the approval of Dextenza,” Amar Sawhney, PhD, president, CEO and chairman of Ocular Therapeutix, said in the release. “We continue to be in close communication with the FDA to determine the best course of action in an effort to successfully bring Dextenza to market.”